Literature DB >> 581034

Experimental anti-arrhythmic properties of melperone, a neuroleptic butyrophenone.

E N Petersen.   

Abstract

The neuroleptic butyrophenone, melperone, has been compared with antiarrhythmics, neuroleptics, alpha-blockers and beta-blockers in various experimental arrhythmias. Melperone 0.01--1 mg/kg intravenously antagonized ouabain-induced arrhythmias in conscious rabbits to the same degree as propranolol 2 mg/kg and quinidine 10 mg/kg intravenously probably mainly via s CNS depressive effect. It was found to be considerably weaker than propranolol 2 mg/kg, when anaesthetized guinea pigs were used. Melperone 0.1--10 mg/kg was inactive against aconitine-induced arrhythmias. Melperone 1--5 mg/kg antagonized adrenaline-induced arrhythmias in halothane-sensitized guinea pigs like phentolamine 1--5 mg/kg intravenously and was more potent than chlorpromazine, propranolol and quinidine. This study and an electrophysiological study suggest that melperone might be a type III anti-arrhythmic drug, which at the same time depresses CNS and reduces afterload.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 581034     DOI: 10.1111/j.1600-0773.1978.tb02222.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN: 0001-6683


  3 in total

1.  Cardiac electrophysiology of four neuroleptics: melperone, haloperidol, thioridazine and chlorpromazine.

Authors:  P Arlock; B Gullberg; S R Olsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-08       Impact factor: 3.000

2.  Differential actions on rabbit nodal, atrial, Purkinje cell and ventricular potentials of melperone, a bradycardic agent delaying repolarization: effects of hypoxia.

Authors:  J S Millar; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1982-01       Impact factor: 8.739

3.  Electrophysiological effects of melperone on isolated rabbit heart muscles.

Authors:  S Ikeguchi; S Hashimoto; M Horie; M Kadoya; T Konishi; C Kawai
Journal:  Br J Pharmacol       Date:  1988-08       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.